Intermittent PI3Kα/β/δ Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy. Intermittent PI3Kα/β/δ Inhibitor Treatment Alleviates Immunosuppressive Environment in PTEN-null prostate Cancer and facilitate Anti-PD-1 Therapy

Examination of gene expression level in tumor tissue or CD8T cell in vehicle, BAY1082439 (Single dose), BAY1082439 daily/intermittent treatment, BAY1082439 treatment release drug treatment group. Examination of gene expression level in CAP2 CAP8 PC3 and LNCaP cell line in vehicle or BAY1082439 treatment. Examination of gene expression level in spleen CD8T cell in vehicle or intermittent BAY1082439 treatment. Overall design: Examination of gene expression levels using RNA-seq. The Supplementary_data_1.xlsx was added to the records on Jan 10, 2022.

本数据集包含以下三项基因表达水平检测内容：
1. 针对赋形剂(vehicle)对照、单剂量BAY1082439处理、每日/间歇给药BAY1082439处理、BAY1082439缓释给药处理各组的肿瘤组织或CD8T细胞(CD8T cell)，开展基因表达水平检测；
2. 针对CAP2、CAP8、PC3及LNCaP细胞系在赋形剂或BAY1082439处理后的样本，开展基因表达水平检测；
3. 针对赋形剂对照或间歇给药BAY1082439处理后的脾脏CD8T细胞，开展基因表达水平检测。

总体实验设计：采用RNA测序(RNA-seq)检测基因表达水平。补充数据文件Supplementary_data_1.xlsx已于2022年1月10日补充至本数据集的记录档案中。